SCHEMBL4300767

SCHEMBL4300767

CCOc1ccc(C(=O)NC(C)CN)cc1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.72
KMT2A Q03164 1/20 0.72
NPSR1 Q6W5P4 2/20 0.63
TAS1R3 Q7RTX0 1/20 0.62
TAS1R1 Q7RTX1 1/20 0.62
HPGD P15428 1/20 0.60
PLK1 P53350 1/20 0.59
ACACB O00763 3/20 0.56
RAB9A P51151 3/20 0.55
NPC1 O15118 3/20 0.55
PARP10 Q53GL7 1/20 0.54
TP53 P04637 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
GAA P10253 2/20 0.52
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
CYP1A2 P05177 1/20 0.51
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10294829 0.85 NPSR1 (0.72) MEN1KMT2ANPSR1TAS1R3TAS1R1
SCHEMBL29096093 0.84 CA1 (0.62) MEN1KMT2ATAS1R3TAS1R1HPGD
SCHEMBL4291553 0.81 RAB9A (0.69) MEN1KMT2ANPSR1TAS1R3TAS1R1
SCHEMBL13366245 0.80 TAS1R3 (0.57) MEN1KMT2ANPSR1TAS1R3TAS1R1
SCHEMBL20266293 0.80 TAS1R3 (0.77) MEN1KMT2ANPSR1TAS1R3TAS1R1
SCHEMBL2636457 0.79 PLK1 (0.73) MEN1KMT2ANPSR1TAS1R3TAS1R1
SCHEMBL19781302 0.78 NPSR1 (1.00) MEN1KMT2ANPSR1TAS1R3TAS1R1
SCHEMBL19781301 0.78 NPSR1 (1.00) MEN1KMT2ANPSR1TAS1R3TAS1R1
SCHEMBL6097041 0.77 RAB9A (0.63) MEN1KMT2AHPGDACACBRAB9A
SCHEMBL6097043 0.77 RAB9A (0.63) MEN1KMT2AHPGDACACBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
WO-2008011131-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286791-A1 Amide Compounds DLAT, DGAT2, DGAT1 MEN1 4145/4885KMT2A 710/4885NPSR1 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.